# COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

> **NCT04476953** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 80 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Placebo
- **DRUG:** Fisetin

## Key facts

- **NCT ID:** NCT04476953
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-03
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476953, "COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04476953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*